A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease

Gabriela M. Dieckmann,Stephanie M. Cox,Maria J. Lopez,M. Cuneyt Ozmen,Leyla Yavuz Saricay,Betul N. Bayrakutar,William W. Binotti,Eugenia Henry,Jeffrey Nau,Pedram Hamrah
DOI: https://doi.org/10.1007/s40123-022-00530-x
2022-06-03
Ophthalmology and Therapy
Abstract:Dry eye disease is characterized by a persistently unstable or deficient tear film causing discomfort or visual impairment. Varenicline is a small-molecule nicotinic acetylcholine receptor agonist recently approved for use as a preservative-free nasal spray (OC-01 [varenicline solution] nasal spray [OC-01 VNS]) to treat signs and symptoms of dry eye disease, but its effect on conjunctival goblet cells has not been studied.
ophthalmology
What problem does this paper attempt to address?